Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$165.92+0.61 (+0.37%)
Close on Nov 17, 2026Market cap $16.87BP/E 24.3Yield –
Neurocrine Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Neurocrine Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was $898.10M, up 58.3% year over year. For fiscal 2025 it was $782.70M, up 31.5% from the year before. The highest annual figure on record is $782.70M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $782.70M | +31.5% |
| FY2024 | Dec 31, 2024 | $595.40M | +52.7% |
| FY2023 | Dec 31, 2023 | $389.90M | +14.9% |
| FY2022 | Dec 31, 2022 | $339.40M | +32.3% |
| FY2021 | Dec 31, 2021 | $256.50M | +12.3% |
| FY2020 | Dec 31, 2020 | $228.50M | +55.4% |
| FY2019 | Dec 31, 2019 | $147.00M | +45.0% |
| FY2018 | Dec 31, 2018 | $101.40M | – |
| FY2017 | Dec 31, 2017 | -$94.33M | – |
| FY2016 | Dec 31, 2016 | -$106.18M | – |
| FY2015 | Dec 31, 2015 | -$38.00M | – |
| FY2014 | Dec 31, 2014 | -$47.14M | – |
| FY2013 | Dec 31, 2013 | -$29.61M | – |
| FY2012 | Dec 31, 2012 | -$35.29M | – |
| FY2011 | Dec 31, 2011 | -$698.00K | -101.4% |
| FY2010 | Dec 31, 2010 | $49.94M | – |
| FY2009 | Dec 31, 2009 | -$53.10M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $136.40M | +33.7% |
| Q1 FY2026 | Mar 31, 2026 | $145.80M | +125.0% |
| Q4 FY2025 | Dec 31, 2025 | $388.40M | +60.2% |
| Q3 FY2025 | Sep 30, 2025 | $227.50M | +44.0% |
| Q2 FY2025 | Jun 30, 2025 | $102.00M | +57.9% |
| Q1 FY2025 | Mar 31, 2025 | $64.80M | -50.3% |
| Q4 FY2024 | Dec 31, 2024 | $242.50M | +96.4% |
| Q3 FY2024 | Sep 30, 2024 | $158.00M | -25.5% |
| Q2 FY2024 | Jun 30, 2024 | $64.60M | -64.0% |
| Q1 FY2024 | Mar 31, 2024 | $130.30M | – |
| Q4 FY2023 | Dec 31, 2023 | $123.50M | -13.6% |
| Q3 FY2023 | Sep 30, 2023 | $212.00M | +114.6% |
| Q2 FY2023 | Jun 30, 2023 | $179.60M | +30.1% |
| Q1 FY2023 | Mar 31, 2023 | -$125.20M | – |
| Q4 FY2022 | Dec 31, 2022 | $143.00M | +3304.8% |
| Q3 FY2022 | Sep 30, 2022 | $98.80M | +59.9% |
| Q2 FY2022 | Jun 30, 2022 | $138.10M | +33.8% |
| Q1 FY2022 | Mar 31, 2022 | -$40.50M | -146.4% |
| Q4 FY2021 | Dec 31, 2021 | $4.20M | -95.6% |
| Q3 FY2021 | Sep 30, 2021 | $61.80M | – |
| Q2 FY2021 | Jun 30, 2021 | $103.20M | -13.2% |
| Q1 FY2021 | Mar 31, 2021 | $87.30M | +145.9% |
| Q4 FY2020 | Dec 31, 2020 | $94.50M | -3.1% |
| Q3 FY2020 | Sep 30, 2020 | -$20.40M | -120.9% |
| Q2 FY2020 | Jun 30, 2020 | $118.90M | +85.2% |
| Q1 FY2020 | Mar 31, 2020 | $35.50M | – |
| Q4 FY2019 | Dec 31, 2019 | $97.50M | +93.1% |
| Q3 FY2019 | Sep 30, 2019 | $97.80M | +41.9% |
| Q2 FY2019 | Jun 30, 2019 | $64.20M | +213.5% |
| Q1 FY2019 | Mar 31, 2019 | -$112.50M | – |
| Q4 FY2018 | Dec 31, 2018 | $50.49M | +24.4% |
| Q3 FY2018 | Sep 30, 2018 | $68.92M | – |
| Q2 FY2018 | Jun 30, 2018 | $20.48M | – |
| Q1 FY2018 | Mar 31, 2018 | -$38.49M | – |
| Q4 FY2017 | Dec 31, 2017 | $40.58M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.31M | – |
| Q2 FY2017 | Jun 30, 2017 | -$48.24M | – |
| Q1 FY2017 | Mar 31, 2017 | -$77.36M | – |
| Q4 FY2016 | Dec 31, 2016 | -$31.63M | – |
| Q3 FY2016 | Sep 30, 2016 | -$31.01M | – |
See a number that looks wrong?